Assessment of vascular remodeling under antiangiogenic therapy using DCE-MRI and vessel size imaging.

摘要: Purpose To assess vascular remodeling in tumors during two different antiangiogenic therapies with dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and vessel size to evaluate the index (VSI) as a novel biomarker of therapy response. Materials Methods In independent experiments, nude mice bearing human skin squamous cell carcinoma xenografts were treated endothelial growth factor (VEGF) inhibitor (bevacizumab) or multitargeted tyrosine kinase (SU11248). Changes tumor vascularity assessed by DCE-MRI imaging. data analyzed applying two-compartment model (Brix), calculating parameters Amplitude kep. Results For both experiments decreased significantly while kep did not change significantly. VSI showed controversial results. was increased SU11248-treated A431 tumors, whereas no changes found bevacizumab-treated HaCaT-ras-A-5RT3 tumors. Immunohistology confirmed these results suggest differences maturation vascularization possible explanation. Conclusion DCE-MRI provide reliable supplementing biomarkers response. The methods are excellent agreement histology. Nevertheless, our also indicate that is complex uniform response cannot be expected for therapies. J. Magn. Reson. Imaging 2009;29:1125–1133. © 2009 Wiley-Liss, Inc.